Managing Eye Health for People With Diabetes
This wiki is for patients and health-care workers wanting to learn more about management of diabetic retinopathy.
Latest Topics
Studies: Aflibercept 8 mg for DME (PHOTON trial)
The Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (PHOTON) met its primary endpoint of patients with diabetic macular edema (DME) patients maintained on 12 and 16 week intervals between injections of a unique formulation of aflibercept (8 mg). This 8 mg dose four-fold higher than Eylea (2 mg). Key result was […]
Research news: TRPV2 reduction contributes to loss of blood flow autoregulation in diabetic retinopathy eyes
A study conducted on rats at Queen’s University in Belfast, UK has found that the downregulation of TRPV2 channels in retinal vessel walls is at least partly responsible for the loss of blood flow autoregulation in the retina and the formation of diabetic retinopathy symptoms. Diabetic retinopathy is a leading cause of vision […]
Research news: PANORAMA study shows improvement in diabetic retinopathy severity with anti-VEGF injections
The results of the PANORAMA Study suggest that injection of anti-VEGF drugs into eyes with moderate to severe NPDR reduces the risk of progression to vision-threatening complications. Diabetic retinopathy is a leading cause of vision loss in adults. Current treatments are described here. Regular intravitreal injection of anti-VEGF drugs reduces the severity of both proliferative […]
Research news: Garlic tablets may reduce DME
The results of a small, double-blinded clinical trial suggest that garlic tablets, taken orally, may be an effective complementary therapy for patients with diabetic macular edema (DME) from diabetic retinopathy (DR). Diabetic macular edema is a leading cause of vision loss in adults. Current treatments are described here. Garlic has been shown to have antidiabetic […]
Diabetic macular edema (DME): Treatment with micropulse laser surgery
DME is typically treated with anti-VEGF or triamcinolone steroid injections. For patients who respond poorly or wish to avoid intravitreal injections, laser treatment can be performed. There are two types of laser treatment used to reduce the leakage of fluid from blood vessels that leads to DME: Photocoagulation. This is where the laser is used […]
anti-VEGF drugs: brolucizumab (Beovu)
Brolucizumab (trade name Beovu) was the third anti-VEGF drug approved by the FDA for treatment of DME. The package insert is currently located here. Brolucizumab -dbll is an inhibitor of vascular endothelial growth factor (VEGF) like the other anti-VEGF drugs. It is a humanized monoclonal single-chain variable (Fv) antibody fragment. As such it has a small […]
About the Authors





Topics
- Research news: Garlic tablets may reduce DME
- Research news: PANORAMA study shows improvement in diabetic retinopathy severity with anti-VEGF injections
- Research news: RegenXBio Presents Positive Data From Altitude Trial Of RGX-314 For Treatment Of Diabetic Retinopathy
- Research news: TRPV2 reduction contributes to loss of blood flow autoregulation in diabetic retinopathy eyes